This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Evidence-Based Medicine  • Statistics and Research Methods  • Surgical Interventions, Other  • Review  • Prognosis/ Outcomes  • Drug Therapy  • Alert me on articles by topic

M. Margaret Knudson, MD

Arch Surg. 2008;143(3):304.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In 1999, the US Food and Drug Administration approved the use of rFVIIa for the treatment of bleeding episodes in patients with the inherited coagulation disorder hemophilia A or B and inhibitors to factor VIII or IX. Increasingly, however, this product is being used by surgeons to treat patients with acquired coagulopathy, particularly during surgical procedures in which large blood loss is anticipated, such as cardiac, vascular, and liver transplantation surgery. As experience continues to accumulate and the literature documents its effectiveness, this drug is often administered prophylactically to limit transfusion requirements. However, as outlined in the meta-analysis by Ranucci et al, there is considerable variation across studies in the dose used and in the timing of administration. Because the effectiveness of rFVIIa in promoting clot formation may be affected by other factors, such as the platelet count, the fibrinogen level, and the pH at the . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED ARTICLE

Efficacy and Safety of Recombinant Activated Factor VII in Major Surgical Procedures: Systematic Review and Meta-analysis of Randomized Clinical Trials
Marco Ranucci, Giuseppe Isgrò, Giorgio Soro, Daniela Conti, and Barbara De Toffol
Arch Surg. 2008;143(3):296-304.
ABSTRACT | FULL TEXT